2024
Moving Beyond Devices to Patient Selection A New Frontier in Stroke Prevention After TAVR
Ahmad Y, Lansky A. Moving Beyond Devices to Patient Selection A New Frontier in Stroke Prevention After TAVR. JACC Cardiovascular Interventions 2024, 17: 1691-1692. PMID: 39048256, DOI: 10.1016/j.jcin.2024.06.017.Peer-Reviewed Original Research
2020
Sex-Specific Outcomes in Cardiovascular Device Evaluations
Ghare MI, Tirziu D, Abbott JD, Altin E, Yang Y, Ng V, Grines C, Lansky A. Sex-Specific Outcomes in Cardiovascular Device Evaluations. Journal Of Women's Health 2020, 29: 1246-1255. PMID: 32543268, PMCID: PMC9545802, DOI: 10.1089/jwh.2019.8068.Peer-Reviewed Original ResearchMeSH KeywordsCardiac Resynchronization TherapyDefibrillators, ImplantableFemaleHeart FailureHumansMalePatient SelectionStentsTreatment OutcomeConceptsCoronary revascularizationHeart failureClinical trialsDevice trialsMajor clinical trialsStructural heart diseaseSex-specific outcomesBenefit/risk assessmentCardiac resynchronization defibrillatorImplantable cardioverter defibrillatorVentricular assist deviceBest available careDrug eluting stentsBetter treatment recommendationsCardiovascular outcomesDevice therapyTreatment recommendationsHeart diseaseCardioverter defibrillatorDevice clinical trialsTreatment selectionAvailable careAssist deviceNarrative reviewEluting stents
2019
Validation of the all-comers design: Results of the TARGET-AC substudy
G Toth G, Lansky A, Baumbach A, Kelbæk H, van Royen N, Holmvang L, Janssens L, Brugaletta S, Barbato E, Maillard L, Kiemeneij F, Naber CK, Pucher F, Laursen PN, Ameloot K, Robles C, Milkas A, Sevilla J, Jensen C, Wijns W. Validation of the all-comers design: Results of the TARGET-AC substudy. American Heart Journal 2019, 221: 148-154. PMID: 31924299, DOI: 10.1016/j.ahj.2019.10.019.Peer-Reviewed Original ResearchConceptsComers designRisk factorsNon-ST elevation acute coronary syndromeElevation acute coronary syndromeNER groupReal-world clinical practiceGroup more patientsInternational multicentre registrySignificant valvular diseaseST-elevation infarctionAcute coronary syndromeChronic total occlusionWorld clinical practiceLow inclusion rateMulticentre registryThrombotic stenosisCoronary syndromePrimary PCIStable anginaAngiographic parametersComers populationPatient demographicsStable patientsStudy nursesMore patientsSex Disparities in Cardiovascular Device Evaluations Strategies for Recruitment and Retention of Female Patients in Clinical Device Trials
Ghare MI, Chandrasekhar J, Mehran R, Ng V, Grines C, Lansky A. Sex Disparities in Cardiovascular Device Evaluations Strategies for Recruitment and Retention of Female Patients in Clinical Device Trials. JACC Cardiovascular Interventions 2019, 12: 301-308. PMID: 30732736, DOI: 10.1016/j.jcin.2018.10.048.Peer-Reviewed Original ResearchConceptsTrial participationClinical trialsClinical trial participationUnderrepresentation of womenMultistakeholder engagementGovernment agenciesFemale patientsFemale enrollmentCardiovascular trialsClinical research personnelNarrative reviewDevice trialsTrialsWomenParticipationPublic awarenessEducation campaigns
2018
Acute and one-year clinical outcomes following implantation of bioresorbable vascular scaffolds: the ABSORB UK Registry.
Baumbach A, Zaman A, West NEJ, O'Kane P, Egred M, Johnson T, Wheatcroft S, Bowles R, de Belder A, Bouras G, Lansky A, Hill J, Mathur A, de Belder MA, Banning AP. Acute and one-year clinical outcomes following implantation of bioresorbable vascular scaffolds: the ABSORB UK Registry. EuroIntervention 2018, 13: 1554-1560. PMID: 29131802, DOI: 10.4244/eij-d-17-00886.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAcute Coronary SyndromeAdultClinical Decision-MakingCoronary Artery DiseaseCoronary ThrombosisFemaleHumansMaleMiddle AgedPatient SelectionPercutaneous Coronary InterventionPractice Patterns, Physicians'Product Surveillance, PostmarketingProspective StudiesProsthesis DesignRegistriesRisk FactorsTime FactorsTreatment OutcomeUnited KingdomConceptsBioresorbable vascular scaffoldDe novo coronary lesionsOne-year clinical outcomesIndependent clinical events committeeMajor adverse cardiac eventsAbsorb bioresorbable vascular scaffoldCareful implantation techniqueAdverse cardiac eventsNovo coronary lesionsTarget lesion failureAcute coronary syndromeClinical events committeeB2/CCareful patient selectionContemporary drug-eluting stentsDrug-eluting stentsVascular scaffoldsSmall vessel sizeDefinite STCoronary syndromeLesion failureCardiac eventsPatient ageReal-world practiceBVS implantation
2013
Selection and timing for invasive therapy in non-ST-segment-elevation acute coronary syndrome
Meier P, Fröhlich GM, Meller S, De Palma R, Lansky AJ. Selection and timing for invasive therapy in non-ST-segment-elevation acute coronary syndrome. Expert Review Of Cardiovascular Therapy 2013, 11: 437-445. PMID: 23570357, DOI: 10.1586/erc.13.23.Peer-Reviewed Original ResearchConceptsSegment elevation acute coronary syndromesST-segment elevation myocardial infarctionAcute coronary syndromeCoronary syndromeMyocardial infarctionLong-term mortalityBest treatment strategyOptimal time pointNSTEACS patientsTerm mortalityCoronary angiographyOptimal therapyPoor prognosisTreatment strategiesInvasive therapyHigh mortalityOlder agePatientsTime pointsMortalityNSTEACSInfarctionSyndromeTherapyAngiography
2011
Rationale and design of the INFUSE-AMI study: A 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction
Gibson CM, Maehara A, Lansky AJ, Wohrle J, Stuckey T, Dave R, Cox D, Grines C, Dudek D, Steg G, Parise H, Wolff SD, Cristea E, Stone GW. Rationale and design of the INFUSE-AMI study: A 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. American Heart Journal 2011, 161: 478-486.e7. PMID: 21392601, DOI: 10.1016/j.ahj.2010.10.006.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAntithrombinsCoronary OcclusionCoronary ThrombosisEndpoint DeterminationHirudinsHumansImmunoglobulin Fab FragmentsInfusions, Intra-ArterialMagnetic Resonance Imaging, CineMyocardial InfarctionPatient SelectionPeptide FragmentsPlatelet Aggregation InhibitorsRecombinant ProteinsResearch DesignThrombectomyConceptsPrimary percutaneous coronary interventionST-elevation myocardial infarctionPrimary PCIAnterior ST-elevation myocardial infarctionExport aspiration catheterPercutaneous coronary interventionLocal infusionThrombus aspirationInfarct sizeINFUSE-AMIEnd pointCoronary interventionAspiration catheterMyocardial infarctionInfusion catheterAnterior ST-segment elevation myocardial infarctionST-segment elevation myocardial infarctionSingle-blind randomized studyCardiac magnetic resonance imagingMyocardial infarction 0Mid-left anteriorPrimary end pointSafety end pointSecondary end pointsST-segment resolution
2010
Selection Criteria for Drug-Eluting Versus Bare-Metal Stents and the Impact of Routine Angiographic Follow-Up 2-Year Insights From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Stone GW, Parise H, Witzenbichler B, Kirtane A, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Lansky AJ, Mehran R. Selection Criteria for Drug-Eluting Versus Bare-Metal Stents and the Impact of Routine Angiographic Follow-Up 2-Year Insights From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. Journal Of The American College Of Cardiology 2010, 56: 1597-1604. PMID: 20888162, DOI: 10.1016/j.jacc.2010.08.608.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPaclitaxel-eluting stentsBare metal stentsDrug-eluting stentsElevation myocardial infarctionRisk factorsMyocardial infarctionClinical benefitVersus Bare-Metal StentsAbsolute incremental benefitHORIZONS-AMI trialBaseline risk factorsReference vessel diameterAngiographic Follow-upAbsolute treatment effectLesion revascularizationTLR proceduresTLR rateDiabetes mellitusIndependent predictorsRisk strataFollow-upRisk groupsHigh riskAntirestenotic propertiesImpact of Bivalirudin Therapy in High-Risk Patients With Acute Myocardial Infarction 1-Year Results From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial
Parodi G, Antoniucci D, Nikolsky E, Witzenbichler B, Guagliumi G, Peruga JZ, Stuckey T, Dudek D, Kornowski R, Hartmann F, Lansky AJ, Mehran R, Stone GW. Impact of Bivalirudin Therapy in High-Risk Patients With Acute Myocardial Infarction 1-Year Results From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2010, 3: 796-802. PMID: 20723849, DOI: 10.1016/j.jcin.2010.05.009.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAntithrombinsChi-Square DistributionEptifibatideEuropeFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansImmunoglobulin Fab FragmentsIsraelKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPatient SelectionPeptide FragmentsPeptidesPlatelet Aggregation InhibitorsProspective StudiesRecombinant ProteinsRisk AssessmentRisk FactorsSecondary PreventionStentsTime FactorsTreatment OutcomeUnited StatesConceptsGlycoprotein IIb/IIIa inhibitorsHORIZONS-AMI trialHigh-risk patientsAcute myocardial infarctionRecurrent myocardial infarctionUnfractionated heparinMyocardial infarctionHigh riskPrimary percutaneous coronary interventionIIb/IIIa inhibitorsBaseline patient riskCADILLAC risk scoreIntermediate-risk groupPrimary percutaneous interventionPercutaneous coronary interventionHigh-risk groupLow-risk groupBivalirudin therapyMajor bleedingTrial patientsCoronary interventionIntermediate riskClinical variablesPercutaneous interventionPatient risk
2009
Intravascular Ultrasound Comparison of the Retrograde Versus Antegrade Approach to Percutaneous Intervention for Chronic Total Coronary Occlusions
Tsujita K, Maehara A, Mintz GS, Kubo T, Doi H, Lansky AJ, Stone GW, Moses JW, Leon MB, Ochiai M. Intravascular Ultrasound Comparison of the Retrograde Versus Antegrade Approach to Percutaneous Intervention for Chronic Total Coronary Occlusions. JACC Cardiovascular Interventions 2009, 2: 846-854. PMID: 19778773, DOI: 10.1016/j.jcin.2009.06.012.Peer-Reviewed Original ResearchConceptsRetrograde approachRetro groupAntegrade approachMyocardial Infarction flow grade 3Chronic total occlusion techniqueChronic total coronary occlusionsIntravascular Ultrasound ComparisonTotal coronary occlusionMinimum stent areaAngiographic extravasationRCA CTOsIntravascular ultrasound imagingCoronary perforationCTO lengthCTO lesionsCoronary occlusionCTO interventionGuidewire crossingPercutaneous interventionUltrasound comparisonCTO segmentGrade 3Stent areaOcclusion techniqueIntravascular ultrasoundTreatment of left main and multivessel disease in the drug-eluting stent era.
Ng VG, Lansky AJ. Treatment of left main and multivessel disease in the drug-eluting stent era. Reviews In Cardiovascular Medicine 2009, 10 Suppl 2: s24-33. PMID: 19898278, DOI: 10.3909/ricm10s20004.Peer-Reviewed Original ResearchConceptsDrug-eluting stentsBypass surgeryMultivessel coronary artery diseaseCoronary artery bypass surgeryDrug-eluting stent eraArtery bypass surgeryHigh-risk patientsPercutaneous coronary interventionCoronary artery diseaseSignificant survival advantageAlternative treatment modalityStandard of careBare metal stentsMultivessel diseaseRepeat revascularizationCoronary interventionArtery diseaseMedical managementStent eraBalloon angioplastyNonrandomized studyLabel useTreatment modalitiesInvasive strategyClinical trials
2004
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: Design and rationale of the SYNERGY Library
Petersen JL, Mahaffey KW, Becker RC, Goodman SG, Kleiman NS, Marian AJ, Stone GW, Lansky AJ, Lincoff AM, Hazen SL, Nessel CC, Toro-Figueroa L, Tate L, Reist CJ, Cohen M, Califf RM, Ferguson JJ. Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: Design and rationale of the SYNERGY Library. American Heart Journal 2004, 148: 269-276. PMID: 15308996, DOI: 10.1016/j.ahj.2004.03.022.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeHigh-risk patientsCoronary syndromeClinical trialsGlycoprotein IIb/IIIa Inhibitors (SYNERGY) trialSegment elevation acute coronary syndromesElevation acute coronary syndromeCore laboratory facilityEffect of enoxaparinCardiovascular clinical trialsNovel pharmacologic targetsHigh-risk conditionsFurther drug developmentSYNERGY patientsInflammatory markersInhibitor trialsMulticenter trialCoronary arteriogramsUnfractionated heparinPatient populationMyocardial infarctionCoagulation studiesPharmacologic targetPatientsEnoxaparin
2000
Procedural results and intermediate clinical outcomes after multiple saphenous vein graft stenting
Bhargava B, Kornowski R, Mehran R, Kent K, Hong M, Lansky A, Waksman R, Pichard A, Satler L, Leon M. Procedural results and intermediate clinical outcomes after multiple saphenous vein graft stenting. Journal Of The American College Of Cardiology 2000, 35: 389-397. PMID: 10676686, DOI: 10.1016/s0735-1097(99)00564-1.Peer-Reviewed Original ResearchConceptsMid-term clinical outcomesSVG interventionClinical outcomesProcedural successOverall cardiac event-free survivalCardiac event-free survivalSaphenous vein graft angioplastyNon-Q-wave MIHospital procedural successVein graft angioplastyEvent-free survivalIntermediate clinical outcomesMajor complication rateOverall procedural successSaphenous vein graftsGraft angioplastyLesion revascularizationSimultaneous stentingSVG diseaseSVG groupSVG stentingLate mortalityComplication rateDistal embolizationMI rates
1996
Contemporary stent designs: Technical considerations, complications, role of intravascular ultrasound, and anticoagulation therapy
Popma J, Lansky A, Ito S, Mintz G, Leon M. Contemporary stent designs: Technical considerations, complications, role of intravascular ultrasound, and anticoagulation therapy. Progress In Cardiovascular Diseases 1996, 39: 111-128. PMID: 8841006, DOI: 10.1016/s0033-0620(96)80021-1.Peer-Reviewed Original ResearchConceptsBalloon angioplastyIntravascular ultrasoundSaphenous vein graft diseaseClinical useLate clinical benefitNative coronary arteriesVein graft diseaseStent designCurrent antiplateletAnticoagulation therapyAntithrombotic therapyGraft diseaseAdjunct therapyClinical benefitCoronary arteryStent placementDiffuse diseaseStent useBifurcation stenosisTherapySmall vesselsAngioplastyComplicationsNumber of studiesDisease